Free tool
FAERS Monitor: Gliadel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020637 or its brand name (Gliadel, Carmustine). Reports on generic versions are filed under their own applications.
Reports
4,717
Serious
4,619
98% of reports
Hospitalization
1,484
Death reported
1,214
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use521
- febrile neutropenia400
- myelodysplastic syndrome301
- disease progression292
- mucosal inflammation256
- thrombocytopenia252
- pyrexia242
- neutropenia211
- pneumonia206
- drug ineffective202
- infection183
- acute myeloid leukaemia172
- diarrhoea162
- sepsis162
- product use in unapproved indication157
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 112 |
| 2006 | 105 |
| 2007 | 118 |
| 2008 | 134 |
| 2009 | 103 |
| 2010 | 90 |
| 2011 | 147 |
| 2012 | 144 |
| 2013 | 139 |
| 2014 | 101 |
| 2015 | 194 |
| 2016 | 126 |
| 2017 | 247 |
| 2018 | 337 |
| 2019 | 351 |
| 2020 | 375 |
| 2021 | 311 |
| 2022 | 292 |
| 2023 | 440 |
| 2024 | 298 |
| 2025 | 229 |
| 2026 | 232 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,442 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelodysplastic syndromeSignal | 301 | 94.7 | 84.8 | 27,266 |
| acute myeloid leukaemiaSignal | 172 | 49.7 | 42.9 | 8,083 |
| mucosal inflammationSignal | 256 | 44.0 | 39.1 | 10,629 |
| febrile neutropeniaSignal | 400 | 27.0 | 24.6 | 9,978 |
| disease progressionSignal | 292 | 11.0 | 9.9 | 2,661 |
| thrombocytopeniaSignal | 252 | 10.1 | 8.9 | 2,056 |
| neutropeniaSignal | 211 | 6.9 | 6.1 | 1,070 |
| sepsisSignal | 162 | 6.5 | 5.6 | 749 |
| infectionSignal | 183 | 5.6 | 4.9 | 699 |
| pyrexiaSignal | 242 | 3.1 | 2.8 | 352 |
| pneumoniaSignal | 206 | 2.8 | 2.5 | 247 |
| product use in unapproved indicationSignal | 157 | 2.8 | 2.4 | 185 |
| off label useSignal | 521 | 2.7 | 2.4 | 558 |
| diarrhoea | 162 | 1.1 | 1.0 | 2 |
| drug ineffective | 202 | 0.7 | 0.6 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.